Switching from first or second generation EGFR-TKI to osimertinib in mutation-positive NSCLC.

AIM

We evaluated the efficacy of a novel switch protocol for EGFR-TKIs for mutation-positive NSCLC.

MATERIALS & METHODS: Clinical records were collected from the patients who had received one of two sequential combination strategies of EGFR-TKIs: Salvage use of osimertinib for -mediated acquired resistance to an prior EGFR-TKI or switch use of osimertinib where an EGFR-TKI was switched to osimertinib before disease progression.

RESULTS

Progression-free survival of osimertinib and time from the start of treatment until progression to osimertinib was comparable between the salvage use and switch use of osimertinib.

CONCLUSION

Switch use of osimertinib seemed to produce improved efficacy for patients with activating mutations, because of the lack of patient selection via .